Aurinia Pharmaceuticals (AUPH) Announces Quarterly Earnings Results
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.04), Morningstar.com reports. The company had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.07 million. Aurinia Pharmaceuticals had a negative return on equity of 30.34% and a negative net margin of 12,536.05%.
Shares of AUPH traded up $0.05 during trading hours on Friday, reaching $5.65. The company’s stock had a trading volume of 883,496 shares, compared to its average volume of 444,432. The company has a market capitalization of $476.10 million, a price-to-earnings ratio of -6.14 and a beta of 2.22. Aurinia Pharmaceuticals has a 1-year low of $4.41 and a 1-year high of $6.69.
AUPH has been the topic of several recent analyst reports. BidaskClub upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. Zacks Investment Research upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a report on Monday, July 16th. Cantor Fitzgerald set a $18.00 target price on Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, August 11th. HC Wainwright upped their target price on Aurinia Pharmaceuticals to $15.00 and gave the company a “buy” rating in a report on Monday, August 13th. Finally, ValuEngine upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $11.79.
WARNING: This article was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://theolympiareport.com/2018/11/10/aurinia-pharmaceuticals-auph-announces-quarterly-earnings-results.html.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Featured Article: The risks of owning bonds
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.